ACTU · CIK 0001652935 · operating
Actuate Therapeutics is a clinical-stage biopharmaceutical company focused on developing oncology treatments. The company's lead asset is elraglusib injection, a glycogen synthase kinase-3 inhibitor currently in Phase 2 development for metastatic pancreatic ductal adenocarcinoma. Elraglusib is also being evaluated in a Phase 1/2 trial across multiple indications, including refractory pediatric malignancies such as Ewing sarcoma, as well as metastatic melanoma and colorectal cancer.
The company operates as a clinical-development entity with no approved products or disclosed revenue streams. It maintains a small operational footprint with approximately 10 full-time employees and is headquartered in Fort Worth, Texas. Actuate was incorporated in Delaware in 2015 and rebranded from Apotheca Therapeutics in October of that year. The company is listed on Nasdaq.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-3.26 | $-3.26 | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2024-12-31 | 2025-03-13 | 0001683168-25-001581 | SEC ↗ |